Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05458817
Other study ID # 20148
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 1, 2022
Est. completion date May 31, 2025

Study information

Verified date January 2023
Source Tartu University Hospital
Contact Mark Braschinsky, MD, PhD
Phone +3727318501
Email mark.braschinsky@kliinikum.ee
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main aim of the research: To develop an interdisciplinary treatment platform based on digital technology and test the operation and effectiveness of digital interventions in comparison with conventional multidisciplinary treatment or treatment standards (incl. Paper diary, nurse counseling, physiotherapy, cognitive-behavioral therapy).


Description:

Aims and purpose: The main aim of the research: To develop an interdisciplinary treatment platform based on digital technology and test the operation and effectiveness of digital interventions in comparison with conventional multidisciplinary treatment or treatment standards (incl. Paper diary, nurse counseling, physiotherapy, cognitive-behavioral therapy). Sub-aims: To evaluate the effectiveness of interventions based on digital technology and their impact on the quality of life, comparing them with the interventions or treatment standards performed by ordinary specialists. Assess the applicability and accessibility of digital technology-based interventions in the healthcare system against a treatment standard. Determine the profile of patients (demographic and clinical indicators). Identify restrictions on the use of digital interventions. Evaluate patient compliance, non-specific treatment factors such as therapeutic relationship, and treatment credibility against the treatment standard. Evaluate patient satisfaction with treatment methods and impact on treatment outcomes. Assess the satisfaction of professionals with the implementation of a digital multidisciplinary treatment platform in patients. Assess the use and generalization of digitally acquired skills in everyday practice. Determine if and how much clinical contact is needed for digital-based interventions to be effective. Evaluate cost-effectiveness against the standard of treatment. Assess the willingness to pay for the use of an effective headache treatment platform.


Recruitment information / eligibility

Status Recruiting
Enrollment 600
Est. completion date May 31, 2025
Est. primary completion date January 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria: 1. diagnosed migraine, frequent episodic, headache days a month 8-14 days; 2. patient age 18-64 years; 3. very good command of the Estonian language both orally and in writing. Exclusion Criteria: 1. headaches lasting less than 8 days and more than 14 days per month; 2. all other primary and/or secondary diagnoses of headache; 3. under the age of 18 or over 64; 4. currently severe depression; 5. psychotic disorders; 6. pregnancy and lactation; 7. severe somatic disease; 8. severe organic mental disorders; 9. other chronic pain; 10. addictive disorders.

Study Design


Intervention

Other:
digital platform
Patients in the digital group complete the tests in the patient's mobile application and/or in the Internet-based research environment of the Institute of Psychology of the University of Tartu kaemus.psych.ut.ee. Patients and specialists of the control group fill in the tests and the satisfaction questionnaire in the kaemus.psych.ut.ee environment.

Locations

Country Name City State
Estonia Tartu University Hospital Tartu

Sponsors (2)

Lead Sponsor Collaborator
Tartu University Hospital University of Tartu

Country where clinical trial is conducted

Estonia, 

Outcome

Type Measure Description Time frame Safety issue
Primary headache frequency headache diary: number of headache days per month 3 months
Primary headache frequency headache diary: number of headache days per month 6 months
Primary headache frequency headache diary: number of headache days per month 9 months
Secondary medication use headache diary: number of headache days per month 3 months
Secondary medication use headache diary: number of headache days per month 6 months
Secondary medication use headache diary: number of headache days per month 9 months
Secondary The effect of headaches on everyday life Headache Impact Test (HIT-6) 3 months
Secondary The effect of headaches on everyday life Headache Impact Test (HIT-6) 6 months
Secondary The effect of headaches on everyday life Headache Impact Test (HIT-6) 9 months
Secondary Pain acceptance Pain acceptance Pain acceptance Chronic Pain Acceptance Questionnaire-Revised (CPAQ-R) 3 months
Secondary Pain acceptance Pain acceptance Pain acceptance Chronic Pain Acceptance Questionnaire-Revised (CPAQ-R) 6 months
Secondary Pain acceptance Pain acceptance Pain acceptance Chronic Pain Acceptance Questionnaire-Revised (CPAQ-R) 9 months
Secondary Pain-related anxiety Pain Anxiety Symptoms Scale (PASS) 3 months
Secondary Pain-related anxiety Pain Anxiety Symptoms Scale (PASS) 6 months
Secondary Pain-related anxiety Pain Anxiety Symptoms Scale (PASS) 9 months
Secondary Health related quality of life EUROHIS-QOL 8-item index (shortened version of the World Health Organization Quality of Life Instrument-Abbreviated Version) 3 months
Secondary Health related quality of life EUROHIS-QOL 8-item index (shortened version of the World Health Organization Quality of Life Instrument-Abbreviated Version) 6 months
Secondary Health related quality of life EUROHIS-QOL 8-item index (shortened version of the World Health Organization Quality of Life Instrument-Abbreviated Version) 9 months
Secondary Patient satisfaction with treatment 1 Headache Attributed Lost Time (HALT) 3 months
Secondary Patient satisfaction with treatment 2 Headache Under-Response to Treatment (HURT) 3 months
Secondary Patient satisfaction with treatment 3 Headache Attributed Lost Time (HALT) 6 months
Secondary Patient satisfaction with treatment 4 Headache Under-Response to Treatment (HURT) 6 months
Secondary Patient satisfaction with treatment 5 Headache Attributed Lost Time (HALT) 9 months
Secondary Patient satisfaction with treatment 6 Headache Under-Response to Treatment (HURT) 9 months
Secondary Cost-effectiveness 1 databases of the Estonian Health Insurance Fund, the Social Insurance Board and the Institute for Health Development (insurance costs per patient - sick leaves compensation) 9 months
Secondary Cost-effectiveness 2 databases of the Estonian Health Insurance Fund, the Social Insurance Board and the Institute for Health Development (insurance costs per patient - medications reimbursement) 9 months
Secondary Patient's willingness to pay for headache treatment Willingness to pay bidding game 9 months
See also
  Status Clinical Trial Phase
Completed NCT06192173 - Patent Foramen Ovale Closure in Migraine
Completed NCT05525611 - Cabergoline as a Preventive Treatment for Chronic Migraine N/A
Recruiting NCT03832998 - Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine Phase 3
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Not yet recruiting NCT06428838 - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context Phase 3
Completed NCT06304675 - Manageable Environmental Factors in Migraine
Completed NCT04084314 - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Phase 4
Recruiting NCT05517200 - Pilot Study for a Machine Learning Test for Migraine
Completed NCT04179474 - Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine Phase 1
Recruiting NCT04603976 - Registry for Migraine - Clinical Core Phase 4
Completed NCT03597529 - CHOCOlate MeLatonin for AdolescenT MigrainE Phase 2
Completed NCT04197349 - Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman Phase 1
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Active, not recruiting NCT05064371 - Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan Phase 3
Suspended NCT04069572 - Vibratory Stimulation for the Treatment of Chronic Pain N/A
Not yet recruiting NCT04859374 - Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach N/A
Not yet recruiting NCT03083860 - Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions. N/A
Completed NCT02905227 - A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder Phase 1
Enrolling by invitation NCT02532023 - The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients Phase 4
Completed NCT02108678 - One-Day Intervention for Depression and Impairment in Migraine Patients N/A